ルセオグリフロジン

Also known as LSO710, Luseogliflozin

Luseogliflozin (trade name Lusefi) is a pharmaceutical drug (an SGLT2 inhibitor) used for the treatment of type 2 diabetes mellitus. It was approved for use in Japan in 2014. In a meta-analysis involving data from 10 randomized controlled trials (1304 patients), Dutta et. al. demonstrated the good glycaemic efficacy (mean glycated hemoglobin reduction of -0.76% and mean fasting glucose reduction of -26.69mg/dl) and safety of luseogliflozin 2.5mg/day as compared to placebo. Additional benefits include significant reduction in systolic blood pressure (-4.19 mm Hg), serum triglycerides (-12.60mg/

Wikidata facts

Mass: 434.176

Show 5 more facts

Commons category: Luseogliflozin
canonical SMILES: CCOC1=CC=C(C=C1)CC2=C(C=C(C(=C2)C3C(C(C(C(S3)CO)O)O)O)OC)C
chemical formula: C₂₃H₃₀O₆S
isomeric SMILES: CCOC1=CC=C(C=C1)CC2=C(C=C(C(=C2)[C@H]3[C@@H]([C@H]([C@@H]([C@H](S3)CO)O)O)O)OC)C
World Health Organisation international non-proprietary name: luseogliflozin

Sources (5)